EIF2A and Parkinson disease: Although GSK2606414 is not suitable for applications to human PD patients due to its pancreatic toxicity [47], these findings indicate that targeting erUPR pathway and eIF2α phosphorylation hold promise towards the prevention of neurodegeneration in PD.